Peps
Abaloparatide
Abaloparatide is a bone-forming prescription medicine for osteoporosis. Its clinically relevant outcome is prevention of fractures in appropriately selected patients.
Prescription medicines
Read the risks →Peptides that flag kidney problems
These 16 profiles mention kidney problems in their Risks & interactions section, from the FDA label for approved drugs or from published studies for research compounds. Open a profile and read that section to see exactly why.
A peptide that isn't listed may simply have no human safety data, which doesn't make it safe for you. Dashed tags on investigational GLP-1 drugs come from the labels of approved drugs in the same class. Not medical advice: talk to a doctor or pharmacist about your own situation. All peptides · Heart or blood pressure problems · Blood thinners or bleeding problems · Diabetes or blood-sugar medicines · Cancer, now or in the past · Pregnancy or breastfeeding · Liver problems
Desmopressin
Desmopressin is a hormone analogue used in specific water-balance and related conditions. Its effects depend on the formulation and clinical setting.
Prescription medicines
Read the risks →
Dulaglutide
Dulaglutide, marketed as Trulicity, is a long-acting GLP-1 receptor agonist used in type 2 diabetes care. Its research includes blood-sugar control and cardiovascular outcomes.
Prescription medicines
Read the risks →
Efpeglenatide
Efpeglenatide is an exendin-based GLP-1 receptor agonist. AMPLITUDE-O examined cardiovascular and kidney outcomes in a high-risk type 2 diabetes population.
Research topics
Read the risks →
Exenatide
Exenatide is an incretin medicine used in type 2 diabetes. Short-acting and extended-release products need to be distinguished when reading evidence.
Prescription medicines
Read the risks →
Liraglutide
Liraglutide is an incretin medicine with distinct diabetes and weight-management product contexts. Its benefits should be tied to the exact indication and population.
Prescription medicines
Read the risks →
Lixisenatide
Lixisenatide is a GLP-1 receptor agonist. ELIXA studied cardiovascular safety in people with type 2 diabetes who had recently experienced an acute coronary event.
Research topics
Read the risks →
Mazdutide
Mazdutide is a dual GLP-1 and glucagon receptor agonist studied for weight management. GLORY-1 tested it in Chinese adults with overweight or obesity.
Research topics
Read the risks →
Melanotan II
Melanotan II is an experimental melanocortin analogue studied for pigmentation. It is distinct from Melanotan I and other melanocortin medicines.
Research topics
Read the risks →
Pemvidutide
Pemvidutide is a dual GLP-1 and glucagon receptor agonist investigated in metabolic dysfunction-associated steatohepatitis (MASH). Its liver-biopsy outcomes should be separated from weight-loss claims.
Research topics
Read the risks →
Retatrutide
Retatrutide is a triple-receptor agonist investigated for obesity and related metabolic conditions. Its trial identity differs from unverified coded seller listings.
Investigational
Read the risks →
Semaglutide
Semaglutide is an incretin medicine with product-specific uses in diabetes, weight management, and other defined conditions. Brand and formulation matter.
Prescription medicines
Read the risks →
Survodutide
Survodutide is a dual GLP-1 and glucagon receptor agonist. A 2026 phase 3 publication reports weight outcomes in adults with obesity or overweight without diabetes.
Research topics
Read the risks →
Teriparatide
Teriparatide is a parathyroid-hormone-related medicine used in osteoporosis care. Fracture reduction is a more direct clinical outcome than a bone marker alone.
Prescription medicines
Read the risks →
Tirzepatide
Tirzepatide is a dual-incretin medicine with distinct product and indication contexts. Its clinical-trial material is not interchangeable with a research-use vial.
Prescription medicines
Read the risks →
Vosoritide
Vosoritide is a C-type natriuretic peptide analogue studied for growth in children with achondroplasia. Its disease-specific evidence does not support height-increase claims for healthy adults.
Prescription medicines
Read the risks →See something wrong on this page? Report a mistake · Corrections